Quality of life and new antipsychotics in schizophrenia. Are patients better off?

International Journal of Social Psychiatry

Volumn 45, Issue 4, 1999, Pages 268-275

  Awad, A George ^a,c   Voruganti, Lakshmi N P ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b WESTERN UNIVERSITY   (Canada)

^c HUMBER RIVER REGIONAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

DRUG TOLERANCE; HUMAN; PATIENT COMPLIANCE; PATIENT SATISFACTION; QUALITY OF LIFE; REVIEW; SCHIZOPHRENIA; SIDE EFFECT;

EID: 0033389273     PISSN: 00207640     EISSN: None     Source Type: Journal    
DOI: 10.1177/002076409904500405     Document Type: Review

References (27)

1. AWAD, A.G. (1992) Quality of life of schizophrenic patients on medications and implications for new drug trials. Hospital and Community Psychiatry, 43, 262-265.
2. AWAD, A.G., VORUGANTI, L.N.P. & HESLEGRAVE, R.J. (1995) The aim of antipsychotic medication - what are they and are they being achieved? CNS Drugs, 4, 8-16.
3. AWAD, A.G., HOGAN, T.P., VORUGANTI, L.N.P. & HESLEGRAVE, R.J. (1995) Patients subjective experiences on antipsychotic medications: implications for outcome and quality of life. International Clinical Psychopharmacology, 10, Suppl. 3, 123-132.
4. AWAD, A.G. (1995) Quality of Life issues in medicated schizophrenics: therapeutic and research implications. In Contemporary Issues in the Treatment of Schizophrenia (eds. C. Shriqui & Hasrallah). Washington: American Psychiatric Press.
5. AWAD, A.G., VORUGANTI, L.N.P. & HESLEGRAVE, R.J. (1997) Measuring quality of life in patients with schizophrenia. PharmacoEconomics, 11, 37-47.
6. AWAD, A.G., VORUGANTI, L.N.P. & HESLEGRAVE, R.J. (1997) A conceptual model of quality of life in schizophrenia: descriptions and preliminary clinical validation. Quality of Life Research, 6, 21-26.
7. AWAD, A.G. & VORUGANTI, L.N.P. (1999) Cost-utility analysis in schizophrenia. The Journal of Clinical Psychiatry, 60, Suppl. 3, 22-26.
8. AWAD, A.G. & VORUGANTI, L.N.P. (1999) Neuroleptics and quality of life in schizophrenia. In Quality of Life and Mental Health Care (eds. S. Priebe, J. Oliver & W. Kaiser). Petersfield, UK: Wrightson Biomedical Publishing.
9. AWAD, A.G. & VORUGANTI, L.N.P. (in press) Antipsychotic medications: how satisfied are our patients? In Patient Satisfaction, Compliance and Outcomes in Schizophrenia (eds. A.G. Awad, J. Hellewell). London: Shire Hall International Ltd.
10. BERGNER, M., BOBBIT, R.A. & CARTER, W.B. ET AL. (1981) The Sickness Impact Profile: development and final version of a health status measure. Medical Care, 19, 787-805.
11. DAVIES, L.M. & DRUMMOND, M.F. (1990) The economic burden of schizophrenia. Psychiatric Bulletin, 14, 522-525.
12. ENDICOTT, J., SPITZER, R.L. & FLEISS, J.L. ET AL. (1976) The Global Assessment Scale: a procedure for measuring overall severity of psychiatric disturbance. Archives of General Psychiatry, 33, 766-771.
13. FLEISHHACKER, W.W., BERGMANN, K.J. & PEROVICH, R. ET AL. (1989) The Hillside Akathisia Scale: a new rating instrument for neuroleptic induced akathisia. Psychopharmacology Bulletin, 25, 222-226.
14. FRANZ, M., LIS, S. & PLUDDEMANN, K. ET AL. (1997) Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients. British Journal of Psychiatry, 170, 422-425.
15. GILL, T.M. & FEINSTEIN, A.R. (1994) A critical appraisal of the quality of life measurements. Journal of The American Medical Association, 272, 619-626.
16. HOGAN, T.P., AWAD, A.G. & EASTWOOD, R.A. (1983) A self-report scale predictive of drug compliance in schizophrenia: reliability and discriminative validity. Psychological Medicine, 13, 177-183.
17. HONIGFELD, G. & PATIN, J. (1990) A two-year clinical and economic follow-up of patients on Clozapine. Hospital and Community Psychiatry, 41, 881-885.
18. KAY, S., FISZBEIN, A. & OPLER (1987) The Positive and Negative Syndrome Scale for Schizophrenia. Schizophrenia Bulletin, 13, 261-276.
19. LEHMAN, A., WARD, N & LINN, L. (1982) Chronic mental patients; the quality of life issue. American Journal of Psychiatry, 139, 1271-1276.
20. LEHMAN, A. (1983) The well-being of chronic mental patients: assessing their quality of life. Archives of General Psychiatry, 40, 369-373.
21. MALM, U., MAY, P.R.A. & DENEKER, S.J. (1981) Evaluations of the quality of life of the schizophrenic outpatient: a check list. Schizophrenia Bulletin, 7, 477-487.
22. MELTZER, H.Y., BURNETT, S. & BASTANI, B. ET AL. (1990) Effects of six months of Clozapine treatment on the quality of life of chronic schizophrenic patients. Hospital and Community Psychiatry, 41, 892-897.
23. MELTZER, H.Y. (1997) Treatment-resistant schizophrenia: the role of Clozapine. Current Medical Research Opinion, 14, 1-20.
24. REVICKI, D.A. & LUCE, B.R. (1995) Methods of pharmacoeconomic evaluation of new medical treatments in psychiatry. Psychopharmacology Bulletin, 31, 57-65.
25. VORUGANTI, L.N.P. & AWAD, A.G. (1997) Comparative Evaluations of Conventional and New Antipsychotic Drugs With Reference to Subjective Tolerability and Side-effects Profile. Proceedings of The 36th Annual Meeting of the College of Neuropsychopharmacology, Puerto Rico, 185.
26. VORUGANTI, L.N.P., HESLEGRAVE, R.J. & AWAD, A.G. ET AL. (1998) Quality of life measurement in schizophrenia: reconciling the quest for subjectivity with the question of reliability. Psychological Medicine, 28, 165-172.
27. WYKES, T. & STUART, E. (1986) The measurement of social behaviour in psychiatric patients: an assessment of the reliability and validity of the SBS Schedule. British Journal of Psychiatry, 148, 1-11.